C4 Therapeutics, Inc. (CCCC) income statement
CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/302% below fair value
$2.53−0.12 (-4.53%)
Close on Nov 17, 2026Market cap $311.25MP/E –Yield –
C4 Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -319.0%
- Net margin
- -289.4%
- Return on equity, FY2025
- -44.4%
Financial strength
- Current ratio
- 5.45
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 162.9%
Valuation
- P/E ratio
- –
- Price to sales
- 8.88
- Price to book
- 1.26
- Dividend yield
- –
See a number that looks wrong?